Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia.

Angenendt L, Bormann E, Pabst C, Alla V, Görlich D, Braun L, Dohlich K, Schwöppe C, Bohlander SK, Arteaga MF, Wethmar K, Hartmann W, Angenendt A, Kessler T, Mesters RM, Stelljes M, Rothenberg-Thurley M, Spiekermann K, Hébert J, Sauvageau G, Valk PJM, Löwenberg B, Serve H, Müller-Tidow C, Lenz G, Wörmann BJ, Sauerland MC, Hiddemann W, Berdel WE, Krug U, Metzeler KH, Mikesch JH, Herold T, Schliemann C.

Leukemia. 2019 Dec;33(12):2830-2841. doi: 10.1038/s41375-019-0505-x. Epub 2019 Jun 10.

PMID:
31182782
2.

Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue Sarcoma.

Kessler T, Baumeier A, Brand C, Grau M, Angenendt L, Harrach S, Stalmann U, Schmidt LH, Gosheger G, Hardes J, Andreou D, Dreischalück J, Lenz G, Wardelmann E, Mesters RM, Schwöppe C, Berdel WE, Hartmann W, Schliemann C.

Transl Oncol. 2018 Dec;11(6):1271-1282. doi: 10.1016/j.tranon.2018.08.004. Epub 2018 Aug 17.

3.

An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia.

Angenendt L, Reuter S, Kentrup D, Benk AS, Neumann F, Hüve J, Martens AC, Schwöppe C, Kessler T, Schmidt LH, Sauer T, Brand C, Mikesch JH, Lenz G, Mesters RM, Müller-Tidow C, Hartmann W, Wardelmann E, Neri D, Berdel WE, Roesli C, Schliemann C.

Leukemia. 2018 Feb;32(2):510-519. doi: 10.1038/leu.2017.208. Epub 2017 Jun 30.

PMID:
28663580
4.

Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis.

Thoennissen GB, Görlich D, Bacher U, Aufenberg T, Hüsken AC, Hansmeier AA, Evers G, Mikesch JH, Fritz F, Bokemeyer C, Müller-Tidow C, Stelljes M, Mesters RM, Krug U, Kropff MH, Thoennissen NH, Berdel WE.

Acta Haematol. 2017;137(3):163-172. doi: 10.1159/000463534. Epub 2017 Apr 12.

5.

Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction.

Stucke-Ring J, Ronnacker J, Brand C, Höltke C, Schliemann C, Kessler T, Schmidt LH, Harrach S, Mantke V, Hintelmann H, Hartmann W, Wardelmann E, Lenz G, Wünsch B, Müller-Tidow C, Mesters RM, Schwöppe C, Berdel WE.

Oncotarget. 2016 Dec 13;7(50):82458-82472. doi: 10.18632/oncotarget.12559.

6.

Ciprofloxacin versus colistin prophylaxis during neutropenia in acute myeloid leukemia: two parallel patient cohorts treated in a single center.

Pohlen M, Marx J, Mellmann A, Becker K, Mesters RM, Mikesch JH, Schliemann C, Lenz G, Müller-Tidow C, Büchner T, Krug U, Stelljes M, Karch H, Peters G, Gerth HU, Görlich D, Berdel WE.

Haematologica. 2016 Oct;101(10):1208-1215. Epub 2016 Jul 28.

7.

Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia.

Büchner T, Krug UO, Peter Gale R, Heinecke A, Sauerland MC, Haferlach C, Schnittger S, Haferlach T, Müller-Tidow C, Stelljes M, Mesters RM, Serve HL, Braess J, Spiekermann K, Staib P, Grüneisen A, Reichle A, Balleisen L, Eimermacher H, Giagounidis A, Rasche H, Lengfelder E, Görlich D, Faldum A, Köpcke W, Hehlmann R, Wörmann BJ, Berdel WE, Hiddemann W.

Leukemia. 2016 Aug;30(8):1781-4. doi: 10.1038/leu.2016.54. Epub 2016 Mar 11. No abstract available.

PMID:
26965440
8.

NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor.

Brand C, Schliemann C, Ring J, Kessler T, Bäumer S, Angenendt L, Mantke V, Ross R, Hintelmann H, Spieker T, Wardelmann E, Mesters RM, Berdel WE, Schwöppe C.

Oncotarget. 2016 Feb 9;7(6):6774-89. doi: 10.18632/oncotarget.6725.

9.

Tumor Growth Inhibition via Occlusion of Tumor Vasculature Induced by N-Terminally PEGylated Retargeted Tissue Factor tTF-NGR.

Brand C, Fröhlich M, Ring J, Schliemann C, Kessler T, Mantke V, König S, Lücke M, Mesters RM, Berdel WE, Schwöppe C.

Mol Pharm. 2015 Oct 5;12(10):3749-58. doi: 10.1021/acs.molpharmaceut.5b00508. Epub 2015 Aug 31.

PMID:
26310827
10.

Low-Energy Ultrasound Treatment Improves Regional Tumor Vessel Infarction by Retargeted Tissue Factor.

Brand C, Dencks S, Schmitz G, Mühlmeister M, Stypmann J, Ross R, Hintelmann H, Schliemann C, Müller-Tidow C, Mesters RM, Berdel WE, Schwöppe C.

J Ultrasound Med. 2015 Jul;34(7):1227-36. doi: 10.7863/ultra.34.7.1227.

PMID:
26112625
11.

Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature.

Börschel N, Schwöppe C, Zerbst C, Angenendt L, Kessler T, Klapper W, Giovannoni L, Elia G, Neri D, Berdel WE, Mesters RM, Schliemann C.

Leuk Res. 2015 Jul;39(7):739-48. doi: 10.1016/j.leukres.2015.04.005. Epub 2015 Apr 17.

PMID:
25934049
12.

Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation.

Schliemann C, Gutbrodt KL, Kerkhoff A, Pohlen M, Wiebe S, Silling G, Angenendt L, Kessler T, Mesters RM, Giovannoni L, Schäfers M, Altvater B, Rossig C, Grünewald I, Wardelmann E, Köhler G, Neri D, Stelljes M, Berdel WE.

Cancer Immunol Res. 2015 May;3(5):547-56. doi: 10.1158/2326-6066.CIR-14-0179. Epub 2015 Feb 11.

13.

Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT.

Sauer T, Silling G, Groth C, Rosenow F, Krug U, Görlich D, Evers G, Albring J, Besoke R, Mesters RM, Müller-Tidow C, Kessler T, Büchner T, Berdel WE, Stelljes M.

Bone Marrow Transplant. 2015 Apr;50(4):485-92. doi: 10.1038/bmt.2014.300. Epub 2015 Jan 19.

PMID:
25599163
14.

Comparison of manual and semi-automatic measuring techniques in MSCT scans of patients with lymphoma: a multicentre study.

Höink AJ, Weßling J, Koch R, Schülke C, Kohlhase N, Wassenaar L, Mesters RM, D'Anastasi M, Fabel M, Wulff A, Pinto dos Santos D, Kießling A, Graser A, Dicken V, Karpitschka M, Bornemann L, Heindel W, Buerke B.

Eur Radiol. 2014 Nov;24(11):2709-18. doi: 10.1007/s00330-014-3283-x. Epub 2014 Sep 6.

PMID:
25192795
15.

Non-invasive monitoring of tumor-vessel infarction by retargeted truncated tissue factor tTF-NGR using multi-modal imaging.

Persigehl T, Ring J, Bremer C, Heindel W, Holtmeier R, Stypmann J, Claesener M, Hermann S, Schäfers M, Zerbst C, Schliemann C, Mesters RM, Berdel WE, Schwöppe C.

Angiogenesis. 2014 Jan;17(1):235-46. doi: 10.1007/s10456-013-9391-4. Epub 2013 Oct 18.

PMID:
24136410
16.

Visceral leishmaniasis clinically mimicking lymphoma.

Evers G, Pohlen M, Berdel WE, Thoennissen NH, Titze U, Köhler G, Weckesser M, Anthoni C, Mesters RM.

Ann Hematol. 2014 May;93(5):885-7. doi: 10.1007/s00277-013-1896-9. Epub 2013 Sep 6. No abstract available.

PMID:
24061787
17.

Plasma protein S residues 37-50 mediate its binding to factor Va and inhibition of blood coagulation.

Heeb MJ, Mesters RM, Fernández JA, Hackeng TM, Nakasone RK, Griffin JH.

Thromb Haemost. 2013 Aug;110(2):275-82. doi: 10.1160/TH12-12-0953. Epub 2013 May 23.

18.

Anticancer therapy by tumor vessel infarction with polyethylene glycol conjugated retargeted tissue factor.

Schwöppe C, Zerbst C, Fröhlich M, Schliemann C, Kessler T, Liersch R, Overkamp L, Holtmeier R, Stypmann J, Dreiling A, König S, Höltke C, Lücke M, Müller-Tidow C, Mesters RM, Berdel WE.

J Med Chem. 2013 Mar 28;56(6):2337-47. doi: 10.1021/jm301669z. Epub 2013 Mar 15.

PMID:
23496322
19.

Role of reduced ADAMTS13 in arterial ischemic stroke: a pediatric cohort study.

Lambers M, Goldenberg NA, Kenet G, Kirkham FJ, Manner D, Bernard T, Mesters RM, Junker R, Stoll M, Nowak-Göttl U.

Ann Neurol. 2013 Jan;73(1):58-64. doi: 10.1002/ana.23735. Epub 2012 Dec 7.

20.

Induced lymphatic sinus hyperplasia in sentinel lymph nodes by VEGF-C as the earliest premetastatic indicator.

Liersch R, Hirakawa S, Berdel WE, Mesters RM, Detmar M.

Int J Oncol. 2012 Dec;41(6):2073-8. doi: 10.3892/ijo.2012.1665. Epub 2012 Oct 16.

21.

High-dose chemotherapy with autologous PBSC transplantation for poor prognosis germ cell tumors: a retrospective monocenter analysis of 44 cases.

Mohr M, Hartig I, Kessler T, Hamisch C, Kliesch S, Krug U, Spieker T, Semik M, Wiebe K, Pühse G, Hertle L, Liersch R, Müller-Tidow C, Mesters RM, Berdel WE.

Bone Marrow Transplant. 2012 Oct;47(10):1321-5. doi: 10.1038/bmt.2012.14. Epub 2012 Feb 13.

PMID:
22327130
22.

Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in Burkitt's and primary mediastinal large B-cell lymphoma.

Pohlen M, Gerth HU, Liersch R, Koschmieder S, Mesters RM, Kessler T, Appelmann I, Müller-Tidow C, Berdel WE.

Am J Hematol. 2011 Dec;86(12):E61-4. doi: 10.1002/ajh.22165. Epub 2011 Sep 2.

23.

Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients.

Brunnberg U, Mohr M, Noppeney R, Dürk HA, Sauerland MC, Müller-Tidow C, Krug U, Koschmieder S, Kessler T, Mesters RM, Schulz C, Kosch M, Büchner T, Ehninger G, Dührsen U, Serve H, Berdel WE.

Ann Oncol. 2012 Apr;23(4):990-6. doi: 10.1093/annonc/mdr346. Epub 2011 Aug 2.

PMID:
21810729
24.

Mimicry of hydroxyurea-induced leg ulcer by distal vena saphena parva insufficiency.

Goerge T, Schellong G, Mesters RM, Berdel WE.

Ann Hematol. 2012 Mar;91(3):471-2. doi: 10.1007/s00277-011-1270-8. Epub 2011 Jun 7. No abstract available.

PMID:
21647582
25.

Concurrent MR blood volume and vessel size estimation in tumors by robust and simultaneous ΔR2 and ΔR2* quantification.

Remmele S, Ring J, Sénégas J, Heindel W, Mesters RM, Bremer C, Persigehl T.

Magn Reson Med. 2011 Jul;66(1):144-53. doi: 10.1002/mrm.22810. Epub 2011 Feb 8.

26.

Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile.

Dreischalück J, Schwöppe C, Spieker T, Kessler T, Tiemann K, Liersch R, Schliemann C, Kreuter M, Kolkmeyer A, Hintelmann H, Mesters RM, Berdel WE.

Int J Oncol. 2010 Dec;37(6):1389-97.

PMID:
21042706
27.

Tissue-factor fusion proteins induce occlusion of tumor vessels.

Schwöppe C, Kessler T, Persigehl T, Liersch R, Hintelmann H, Dreischalück J, Ring J, Bremer C, Heindel W, Mesters RM, Berdel WE.

Thromb Res. 2010 Apr;125 Suppl 2:S143-50. doi: 10.1016/S0049-3848(10)70033-5.

PMID:
20433995
28.

Compounds in clinical Phase III and beyond.

Kessler T, Bayer M, Schwöppe C, Liersch R, Mesters RM, Berdel WE.

Recent Results Cancer Res. 2010;180:137-63. doi: 10.1007/978-3-540-78281-0_9. Review.

PMID:
20033382
29.

Lymphangiogenesis in cancer: current perspectives.

Liersch R, Biermann C, Mesters RM, Berdel WE.

Recent Results Cancer Res. 2010;180:115-35. doi: 10.1007/978-3-540-78281-0_8. Review.

PMID:
20033381
30.

Angiogenesis inhibition in cancer therapy: platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) and their receptors: biological functions and role in malignancy.

Appelmann I, Liersch R, Kessler T, Mesters RM, Berdel WE.

Recent Results Cancer Res. 2010;180:51-81. doi: 10.1007/978-3-540-78281-0_5. Review.

PMID:
20033378
31.

Hereditary thrombocytopenia and acute myeloid leukemia: a common link due to a germline mutation in the AML1 gene.

Appelmann I, Linden T, Rudat A, Mueller-Tidow C, Berdel WE, Mesters RM.

Ann Hematol. 2009 Oct;88(10):1037-8. doi: 10.1007/s00277-009-0722-x. Epub 2009 Apr 1. No abstract available.

PMID:
19337732
32.

Prognostic relevance of angiogenesis in stage III NSCLC receiving multimodality treatment.

Kreuter M, Kropff M, Fischaleck A, Junker K, Gerss J, Heinecke A, Lindermann M, Reinmuth N, Berdel WE, Mesters RM, Thomas M.

Eur Respir J. 2009 Jun;33(6):1383-8. doi: 10.1183/09031936.00121108. Epub 2009 Feb 12.

33.

Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience.

Bieker R, Kessler T, Schwöppe C, Padró T, Persigehl T, Bremer C, Dreischalück J, Kolkmeyer A, Heindel W, Mesters RM, Berdel WE.

Blood. 2009 May 14;113(20):5019-27. doi: 10.1182/blood-2008-04-150318. Epub 2009 Jan 28.

PMID:
19179306
34.

Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.

Bisping G, Wenning D, Kropff M, Gustavus D, Müller-Tidow C, Stelljes M, Munzert G, Hilberg F, Roth GJ, Stefanic M, Volpert S, Mesters RM, Berdel WE, Kienast J.

Clin Cancer Res. 2009 Jan 15;15(2):520-31. doi: 10.1158/1078-0432.CCR-08-1612.

35.

S100A2 induces metastasis in non-small cell lung cancer.

Bulk E, Sargin B, Krug U, Hascher A, Jun Y, Knop M, Kerkhoff C, Gerke V, Liersch R, Mesters RM, Hotfilder M, Marra A, Koschmieder S, Dugas M, Berdel WE, Serve H, Müller-Tidow C.

Clin Cancer Res. 2009 Jan 1;15(1):22-9. doi: 10.1158/1078-0432.CCR-08-0953.

36.

Combined anti-PDGFRalpha and PDGFRbeta targeting in non-small cell lung cancer.

Reinmuth N, Liersch R, Raedel M, Fehrmann F, Fehrmann N, Bayer M, Schwoeppe C, Kessler T, Berdel W, Thomas M, Mesters RM.

Int J Cancer. 2009 Apr 1;124(7):1535-44. doi: 10.1002/ijc.24109.

37.

Fragmentation of intra-peptide and inter-peptide disulfide bonds of proteolytic peptides by nanoESI collision-induced dissociation.

Mormann M, Eble J, Schwöppe C, Mesters RM, Berdel WE, Peter-Katalinić J, Pohlentz G.

Anal Bioanal Chem. 2008 Nov;392(5):831-8. doi: 10.1007/s00216-008-2258-7. Epub 2008 Jul 29.

PMID:
18663433
38.

Generation of fusion proteins for selective occlusion of tumor vessels.

Kessler T, Schwöppe C, Liersch R, Schliemann C, Hintelmann H, Bieker R, Berdel WE, Mesters RM.

Curr Drug Discov Technol. 2008 Mar;5(1):1-8.

PMID:
18537561
39.

Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositis.

Schmidt E, Thoennissen NH, Rudat A, Bieker R, Schliemann C, Mesters RM, Zühlsdorf M, Müller-Tidow C, Berdel WE.

Ann Oncol. 2008 Sep;19(9):1644-9. doi: 10.1093/annonc/mdn179. Epub 2008 May 2.

PMID:
18453519
40.

Adjuvant therapy with small hairpin RNA interference prevents non-small cell lung cancer metastasis development in mice.

Bulk E, Hascher A, Liersch R, Mesters RM, Diederichs S, Sargin B, Gerke V, Hotfilder M, Vormoor J, Berdel WE, Serve H, Müller-Tidow C.

Cancer Res. 2008 Mar 15;68(6):1896-904. doi: 10.1158/0008-5472.CAN-07-2390.

41.

Neoplasia of the kidney--a rare event during pregnancy: part 2.

Bettendorf O, Bierer S, Köhler G, Piechota HJ, Mesters RM, Klockenbusch W.

Eur Urol. 2006 Aug;50(2):375-6. No abstract available.

PMID:
18217223
42.

Expression of VEGF-C and its receptor VEGFR-3 in the bone marrow of patients with acute myeloid leukaemia.

Liersch R, Schliemann C, Bieker R, Hintelmann H, Buechner T, Berdel WE, Mesters RM.

Leuk Res. 2008 Jun;32(6):954-61. Epub 2007 Nov 19.

PMID:
18006056
43.

Downregulation of neuropilin-1 in patients with acute myeloid leukemia treated with thalidomide.

Kreuter M, Steins M, Woelke K, Buechner T, Berdel WE, Mesters RM.

Eur J Haematol. 2007 Nov;79(5):392-7. Epub 2007 Oct 3.

PMID:
17916085
44.

Chemotherapy in metastatic malignant triton tumor: report on two cases.

Thoennissen NH, Schliemann C, Brunnberg U, Schmidt E, Staebler A, Stegger L, Bremer C, Schleicher C, Mesters RM, Müller-Tidow C, Berdel WE.

Oncol Rep. 2007 Oct;18(4):763-7.

PMID:
17786333
45.

Amsacrine containing induction therapy in elderly AML patients: comparison to standard induction regimens in a matched-pair analysis.

Kessler T, Mohr M, Müller-Tidow C, Krug U, Brunnberg U, Mohr B, Schliemann C, Sauerland C, Serve H, Büchner T, Berdel WE, Mesters RM.

Leuk Res. 2008 Mar;32(3):491-4. Epub 2007 Aug 1.

PMID:
17675230
46.

Paracrine interactions of vascular endothelial growth factor and platelet-derived growth factor in endothelial and lung cancer cells.

Reinmuth N, Rensinghoff S, Raedel M, Fehrmann N, Schwöppe C, Kessler T, Bisping G, Hilberg F, Roth GJ, Berdel W, Thomas M, Mesters RM.

Int J Oncol. 2007 Sep;31(3):621-6.

PMID:
17671690
47.

New molecular therapy targets in acute myeloid leukemia.

Krug U, Serve H, Müller-Tidow C, Mesters RM, Steffen B, Büchner T, Berdel WE.

Recent Results Cancer Res. 2007;176:243-62. Review.

PMID:
17607931
48.

Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia.

Schliemann C, Bieker R, Thoennissen N, Gerss J, Liersch R, Kessler T, Büchner T, Berdel WE, Mesters RM.

Leukemia. 2007 Sep;21(9):1901-6. Epub 2007 Jun 28.

PMID:
17597808
49.

Antiangiogenic tumor treatment: early noninvasive monitoring with USPIO-enhanced MR imaging in mice.

Persigehl T, Bieker R, Matuszewski L, Wall A, Kessler T, Kooijman H, Meier N, Ebert W, Berdel WE, Heindel W, Mesters RM, Bremer C.

Radiology. 2007 Aug;244(2):449-56. Epub 2007 Jun 11.

PMID:
17562810
50.

Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity.

Zahiragic L, Schliemann C, Bieker R, Thoennissen NH, Burow K, Kramer C, Zühlsdorf M, Berdel WE, Mesters RM.

Leukemia. 2007 Jun;21(6):1310-2. Epub 2007 Mar 1. No abstract available.

PMID:
17330095

Supplemental Content

Loading ...
Support Center